idea-004 · payer messages

Every line ends in the claim that substantiates it and that claim's own confidence tag, or is marked unsubstantiated. A message set never upgrades a tag, invents a number, or states anything the candidate's intended use does not cover.

Home wearable LED phototherapy with onboard dosimetry — payer messages

Intended use: For use in the home under prescription to deliver phototherapy to newborns of at least 35 weeks gestational age with uncomplicated indirect hyperbilirubinemia whose total serum bilirubin is above the phototherapy threshold but below the escalation-of-care threshold, as an alternative to inpatient readmission for phototherapy.

Messages

Who is eligible: Newborns of at least 35 weeks with uncomplicated indirect hyperbilirubinemia, above the phototherapy threshold and below the escalation-of-care threshold, on a prescription. Infants under 35 weeks, with hemolytic or complicated disease, or at or near escalation are not candidates for this device and are treated where they are treated today. claim 66unconfirmed
The comparator: What you pay for today, for this infant, is a readmission to hospital for phototherapy whose only purpose is holding the baby under a light, or, where home treatment already happens, a fiberoptic blanket rented to the family by a DME (durable medical equipment) supplier. claim 17unconfirmed claim 15unconfirmed
Not the first wearable you will see: Two wrap-style phototherapy garments are already FDA (US Food and Drug Administration)-cleared under the same product code. The closer of them, SnugLit (K251308 (an FDA 510(k) clearance number), decided 2026-01-15), is cleared for hospital and home use, caregiver-administered, across a wider infant population than ours. Its cleared indication claims no dose record. claim 2verified
Regulatory status: Class II (FDA device class II) under 21 CFR (Title 21 of the Code of Federal Regulations) 880.5700, product code LBI, to market via 510(k) (premarket notification) premarket notification. That is a clearance route, not an approval, and the device has not yet been cleared. The classification was checked against the indication above as written: treatment delivery only. claim 1verified
Not a diagnostic, and not billed as one: This device delivers light and makes no bilirubin measurement claim. Bilirubin measurement is a different generic type under a different regulation, 21 CFR 862.1110 (Class II) or 21 CFR 862.1113 (Class I), on the clinical chemistry review panel, and a separate submission. Nothing here bills as a bilirubin test. claim 31verified
Billed under: HCPCS (Healthcare Common Procedure Coding System) E0202 (a HCPCS code for durable medical equipment), "Phototherapy (bilirubin) light with photometer", a Level II code with no termination date. Its descriptor names a photometer, and this device carries one by design. The photometer measures light delivered, not bilirubin. claim 3verified claim 4verified
Two codes, not one: E0202 is the only phototherapy-light code in the national Level II file. The same file carries S9098 (a HCPCS temporary national code), a per-diem home phototherapy service code. claim 4verified
Which code you pay under: Which of the two your plan uses for newborn home phototherapy decides what this device is to you. If you pay home phototherapy under the S9098 per-diem, which bundles equipment with nursing and blood draw, this device is a cost inside a home health provider's day rate, not a line you see. We do not yet know which code the largest birth states use. claim 68unverified
New spend or substitution: Where your plan already pays E0202 for a home blanket, this device takes that blanket's place on the same code. It substitutes inside spend you already have; it does not open a new benefit line. claim 76unverified
Whose budget this is: Newborns are not Medicare beneficiaries. This is a Medicaid and commercial decision, state by state and plan by plan, and no national coverage determination will settle it for you. claim 6unconfirmed
What Medicare pays, for scale only: Medicare's DMEPOS (durable medical equipment, prosthetics, orthotics and supplies) fee schedule carries one line for E0202: a capped rental billed per rental month, non-rural $75.86 (AZ) to $89.25 (AL), with no purchase line. It is Medicare's allowed amount, and it is not your rate. claim 5verified
The one Medicaid rate on record: Louisiana Medicaid lists E0202 at $33.71, with a second, lower entry at $30.90. That is one state's schedule, and nobody working on this has established what unit it pays on: per day, per month, per episode or purchase. claim 44unconfirmed claim 51unconfirmed
The rental-month question: If your plan prices E0202 as Medicare does, per rental month, a home episode expected to last 2-4 days may bill as a full month. Ask us about this before you meet it in claims data. claim 69unverified claim 10unconfirmed
Who bills you: A DME supplier rents the unit to the family and bills your plan. The hospital, the pediatric practice and the family do not. claim 22unconfirmed
Who keeps the saving: A newborn readmission for phototherapy is paid to the hospital per case. Outside capitated or value-based contracts, a readmission avoided is a cost avoided by your plan, not by the hospital. claim 71unverified
Budget impact: We cannot show you one. A 2026 systematic review of 31 home phototherapy studies found no included study evaluating cost-effectiveness. Anyone handing you a per-episode saving for this category has modelled it, not measured it, and we will not model one for you. claim 40unconfirmed
The utilization question you should ask us: The published readmission evidence is thin and points both ways. A 2024 meta-analysis of 9 studies and 998 patients found readmission higher with home than inpatient phototherapy (RR 4.61, 95% CI 1.43-14.86), grading the evidence very low. A 2026 review of 31 studies found a pooled (re)admission rate of 3.5% after home initiation (95% CI 2.2-5.3%), graded low for all outcomes. We are not telling you readmissions fall. claim 39unconfirmed claim 40unconfirmed
Coverage argument: The precedent we would rest on is a state Medicaid coverage policy for newborn home phototherapy. Whether the largest birth states publish one has not been established. It is the first document we would want in front of you, not the last. claim 23unconfirmed
The edit that decides the photometer: Whether your plan denies, reduces or recodes an E0202 claim for a light supplied without a photometer is your rule, not ours. If it does, the photometer is a condition of payment. If it does not, it is descriptor wording. claim 73unverified
What becomes auditable: Each episode returns a record of delivered irradiance and time, tied to the billing record, so what you paid for and what the infant received are in the same document. claim 12unconfirmed claim 27unconfirmed
Monitoring stays where it is: Serum bilirubin monitoring stays with the ordering clinician's outpatient draw, billed as it is today. This device adds no test and no lab code. The home model depends on families making those draws on schedule without a nurse at home. claim 72unverified
Prior authorization: The episode has to start inside a clinical window measured in hours, so an authorization path measured in days works as a denial. claim 67unconfirmed

Beyond intended use

Any message above that asserts a population, setting, duration or outcome the intended use does not state. None. is a valid answer and the honest one for most candidates. An absent section is a failure.

Not none. Four edges, named specifically.

"2-4 days" is a duration the indication does not state. The indication names no episode length. The rental-month question takes 2-4 days from claim 10unconfirmed, where it is a Generator assumption for revenue-per-episode arithmetic, and puts it in front of a payer as an expected episode length. It is framed as a billing-unit question rather than a treatment promise, but a payer will read it as a duration.
The dose record is not in the indication. The indication claims phototherapy delivery only. What becomes auditable offers the record to the payer as a benefit, and The edit that decides the photometer makes it a possible payment condition. Dosimetry lives in the candidate's mechanism:, not in its claimed indication, and how FDA would read a dose-and-adherence record sent to the clinician is itself only on record as an assumption claim 74unverified. Neither message may ever be phrased as the device telling anyone something about the infant's bilirubin.
A code whose descriptor names a photometer is not a measurement claim, and must never read as one. "Phototherapy (bilirubin) light with photometer" reads, to a payer skimming a fee schedule, like a device that measures bilirubin. Billed under says outright that the photometer measures delivered light, and Not a diagnostic, and not billed as one holds that edge shut. The edit that decides the photometer is phrased as a payer's coding rule, never as a clinical capability.
Monitoring sits outside the device, and one message leans on it. Monitoring stays where it is is inside the indication (home, under prescription, bilirubin monitoring left with the clinician), but it states an expectation of family behaviour, on-schedule outpatient draws, that the indication does not claim and that nothing verifies.

Checked and found inside the indication:

The comparator is limited to readmission and the home blanket this time. The 2026-09-03 build also priced the initial birth-hospitalisation bed-day, which the indication ("an alternative to inpatient readmission") does not cover; that framing was dropped rather than flagged a second time. claim 17unconfirmed covers both halves; the copy uses only the half the indication states.
Who is eligible restates the indication's own population and says the excluded infants are not candidates. No message offers the payer a wider eligible population, which would be the easiest way to make the budget arithmetic look better.
Not the first wearable you will see describes a competitor's broader cleared label, attributed to SnugLit by name, and claims none of that population for this device.
Excluded on purpose: the US clinic review that found 4% readmission with a home biliblanket against 13% without claim 38unconfirmed is the one favourable US readmission figure in the file. Its population is newborns discharged with total serum bilirubin below the phototherapy threshold, a population the indication does not cover, so it is not in The utilization question you should ask us. Quoting it to a payer would be promoting prophylactic use.
Regulatory status says "clearance route, not an approval" and says the device is not yet cleared. Prior authorization and Who keeps the saving are statements about the payer's own processes and contracts, not about the device.

What we cannot say yet

Every message above whose backing is not verified. The checker enforces set equality — exactly these lines, no more and no fewer.

Who is eligible: that the exclusion boundary is clinically appropriate, and that excluded infants are treated elsewhere, is a practice-appropriateness question no connector reaches — claim 66unconfirmed
The comparator: neither today's inpatient treatment of this band nor the composition of today's home rental fleet has been checked against a source — claim 17unconfirmed claim 15unconfirmed
Which code you pay under: whether the payers that matter pay home phototherapy under S9098 rather than E0202 was put on record by the business case and has never been attempted by a Verifier; it is the question the viability deck names as load-bearing — claim 68unverified
New spend or substitution: that home blankets are billed to Medicaid and commercial plans under E0202 today is asserted by this set and nowhere else; this build appended it so the Verifier can see it — claim 76unverified
Whose budget this is: the structural point is reasoning, not a lookup, and the Medicaid birth-share behind it is uncited — claim 6unconfirmed
The one Medicaid rate on record: $33.71 is one state's human-attached schedule, unverified against its source, on a billing unit nobody has established — claim 44unconfirmed claim 51unconfirmed
The rental-month question: whether a monthly-rental payer pays a full month for a short episode is an assumption, and the 2-4 day episode length is a Generator figure — claim 69unverified claim 10unconfirmed
Who bills you: that the DME supplier is the billing party and the customer is a business-model assumption no source names — claim 22unconfirmed
Who keeps the saving: that a newborn readmission is paid per case to the hospital by Medicaid and most commercial plans has never been checked against a state hospital payment manual — claim 71unverified
Budget impact: the absence of cost-effectiveness studies comes from a literature scan nobody has appraised, and it is the strongest thing we have to say to a payer — claim 40unconfirmed
The utilization question you should ask us: two meta-analyses located by literature scan, graded very low and low by their own authors, pointing in opposite directions and never appraised here — claim 39unconfirmed claim 40unconfirmed
Coverage argument: no connector reaches state Medicaid policy, and no payer is on record covering this indication; whether any large birth state publishes a policy is an open question, not a favourable one — claim 23unconfirmed
The edit that decides the photometer: the descriptor wording is verified; that any payer enforces it as a payment condition is not, and has never been attempted — claim 73unverified
What becomes auditable: that the dose record is a defensible asset is asserted, and its measurement accuracy in a moving garment has never been benched — claim 12unconfirmed claim 27unconfirmed
Monitoring stays where it is: that families complete the scheduled outpatient draws without in-home nursing was put on record by the desirability deck and has never been attempted — claim 72unverified
Prior authorization: no source establishes any prior-authorization turnaround for home phototherapy, in any state or plan — claim 67unconfirmed

Words on this page10 abbreviation(s) and code(s), with what each stands for — copied from _shared/plain-language.md

21 CFR: Title 21 of the Code of Federal Regulations — the US food-and-drug rulebook; a number after it is one regulation, often the one that classifies a device type
510(k): premarket notification — the FDA route for a device shown to be as safe and effective as one already on the market; months, no clinical trial as a rule
Class II: FDA device class II — moderate-risk devices, usually cleared by 510(k)
DME: durable medical equipment — equipment a patient uses at home, such as a pump or a stimulator, that Medicare pays for under its own rules
DMEPOS: durable medical equipment, prosthetics, orthotics and supplies — the Medicare benefit and fee schedule that home equipment is paid under
E####: a HCPCS code for durable medical equipment — one billing code for a piece of home equipment; the letter E and four digits
FDA: US Food and Drug Administration — the US regulator that clears or approves a device before it can be sold
HCPCS: Healthcare Common Procedure Coding System — the US billing codes for equipment, supplies and some services; a code is how a payer recognises what to pay for
K######: an FDA 510(k) clearance number — the public record of one cleared device; the letter K and six digits
S####: a HCPCS temporary national code — a billing code used by some private payers and not by Medicare

Generated from knowledge-base/messaging/idea-004-payer.md by engine/scripts/build_review.py on 2026-10-04. This page is a view — edit the source file and rebuild, never edit here.